

World Journal of *Hepatology*

Monthly Volume 17 Number 1 January 27, 2025



EDITORIAL

Perazza F, Ravaioli F. Small bites, big impact: The importance of evening snacks in patients with advanced chronic liver disease. *World J Hepatol* 2025; 17(1): 101195 [DOI: [10.4254/wjh.v17.i1.101195](https://doi.org/10.4254/wjh.v17.i1.101195)]

Li T, Li YP. Innovative diagnostic tool aids screening for minimal hepatic encephalopathy in non-alcoholic cirrhosis patients. *World J Hepatol* 2025; 17(1): 101420 [DOI: [10.4254/wjh.v17.i1.101420](https://doi.org/10.4254/wjh.v17.i1.101420)]

REVIEW

Shi J, Zhu X, Yang JB. Advances and challenges in molecular understanding, early detection, and targeted treatment of liver cancer. *World J Hepatol* 2025; 17(1): 102273 [DOI: [10.4254/wjh.v17.i1.102273](https://doi.org/10.4254/wjh.v17.i1.102273)]

MINIREVIEWS

Qiu Y, Tang Q, Liu XQ, Xue YL, Zeng Y, Hu P. Hepatitis B core-related antigen as a promising serological marker for monitoring hepatitis B virus cure. *World J Hepatol* 2025; 17(1): 98658 [DOI: [10.4254/wjh.v17.i1.98658](https://doi.org/10.4254/wjh.v17.i1.98658)]

ORIGINAL ARTICLE**Retrospective Cohort Study**

Carteri RB, Marroni CA, Ferreira LF, Pinto LP, Czermaini J, Tovo CV, Fernandes SA. Do Child-Turcotte-Pugh and nutritional assessments predict survival in cirrhosis: A longitudinal study. *World J Hepatol* 2025; 17(1): 99183 [DOI: [10.4254/wjh.v17.i1.99183](https://doi.org/10.4254/wjh.v17.i1.99183)]

El Labban M, Kotys J, Makher S, Pannala SSS, El Gharib K, Chehab H, Deeb L, Surani SR. Impact of liver cirrhosis on morbidity and mortality of patients admitted to the hospital with necrotizing fasciitis. *World J Hepatol* 2025; 17(1): 102270 [DOI: [10.4254/wjh.v17.i1.102270](https://doi.org/10.4254/wjh.v17.i1.102270)]

Retrospective Study

Jiang ML, Xu F, Li JL, Luo JY, Hu JL, Zeng XQ. Clinical features of abnormal α -fetoprotein in 15 patients with chronic viral hepatitis B after treatment with antiviral drugs. *World J Hepatol* 2025; 17(1): 100392 [DOI: [10.4254/wjh.v17.i1.100392](https://doi.org/10.4254/wjh.v17.i1.100392)]

Observational Study

Ullah H, Huma S, Yasin G, Ashraf M, Tahir N, Tahir Uddin Q, Shabana H, A R Hussein M, Shalaby A, Mossaad Alsayyad M, Said A, Farahat A, Hamed HI, Ayoub HSA, Imam MS, Elmahdi E. Comparison of different severity scores in correlating hemoglobin levels with the severity of hepatic decompensation: An observational study. *World J Hepatol* 2025; 17(1): 101212 [DOI: [10.4254/wjh.v17.i1.101212](https://doi.org/10.4254/wjh.v17.i1.101212)]

Soni J, Pathak N, Gharra M, Aswal D, Parikh J, Sharma P, Mishra A, Lalan D, Maheshwari T. Effectiveness of RESET care program: A real-world-evidence on managing non-alcoholic fatty liver disease through digital health interventions. *World J Hepatol* 2025; 17(1): 101630 [DOI: [10.4254/wjh.v17.i1.101630](https://doi.org/10.4254/wjh.v17.i1.101630)]

Prospective Study

Jespersen S, Fritt-Rasmussen A, Madsbad S, Pedersen BK, Krogh-Madsen R, Weis N. Prevalence of cardiometabolic co-morbidities in patients with vs persons without chronic hepatitis B: The FitLiver cohort study. *World J Hepatol* 2025; 17(1): 97797 [DOI: 10.4254/wjh.v17.i1.97797]

Randomized Controlled Trial

Cano Contreras AD, Del Rocío Francisco M, Vargas Basurto JL, Gonzalez-Gomez KD, Amieva-Balmori M, Roesch Dietlen F, Remes-Troche JM. Effect of alpha-lipoic acid and *Silybum marianum* supplementation with a Mediterranean diet on metabolic dysfunction-associated steatosis. *World J Hepatol* 2025; 17(1): 101704 [DOI: 10.4254/wjh.v17.i1.101704]

META-ANALYSIS

Xu XT, Jiang MJ, Fu YL, Xie F, Li JJ, Meng QH. Gut microbiome composition in patients with liver cirrhosis with and without hepatic encephalopathy: A systematic review and meta-analysis. *World J Hepatol* 2025; 17(1): 100377 [DOI: 10.4254/wjh.v17.i1.100377]

SCIENTOMETRICS

Zhu WY, Li X, Xie JL, Lu Q, Ma YJ, Zhu ZJ, Liu J. Hotspots and trends in stem cell therapy for liver fibrosis and cirrhosis: A bibliometric analysis. *World J Hepatol* 2025; 17(1): 96105 [DOI: 10.4254/wjh.v17.i1.96105]

Huang CY, Luo ZZ, Huang WP, Lin LP, Yao YT, Zhuang HX, Xu QY, Lai YD. Research hotspots and trends in gut microbiota and nonalcoholic fatty liver disease: A bibliometric study. *World J Hepatol* 2025; 17(1): 102034 [DOI: 10.4254/wjh.v17.i1.102034]

CASE REPORT

Chen ZQ, Zeng SJ, Xu C. Management of chylous ascites after liver cirrhosis: A case report. *World J Hepatol* 2025; 17(1): 100797 [DOI: 10.4254/wjh.v17.i1.100797]

Le KL, Tran MQ, Pham TN, Duong NNQ, Dinh TT, Le NK. Hepatic eosinophilic pseudotumor due to *Fasciola hepatica* infection mimicking intrahepatic cholangiocarcinoma: A case report. *World J Hepatol* 2025; 17(1): 101664 [DOI: 10.4254/wjh.v17.i1.101664]

LETTER TO THE EDITOR

Kanda T, Sasaki-Tanaka R, Tsuchiya A, Terai S. Hepatitis B virus infection and its treatment in Eastern Ethiopia. *World J Hepatol* 2025; 17(1): 99209 [DOI: 10.4254/wjh.v17.i1.99209]

Majeed AA, Butt AS. Hepatitis B virus infection and metabolic dysfunction associated steatotic liver disease: Rising pandemic with complex interaction. *World J Hepatol* 2025; 17(1): 100968 [DOI: 10.4254/wjh.v17.i1.100968]

Emiroglu HH, Emiroglu M. Timing of post-vaccination tests in infants born to mothers with chronic hepatitis B virus infection. *World J Hepatol* 2025; 17(1): 101619 [DOI: 10.4254/wjh.v17.i1.101619]

Gou GE, Li T, Liu CR, Meng T, Li YP. Potential mechanisms and therapeutic prospects of the association between *Helicobacter pylori* infection and metabolic dysfunction-associated steatohepatitis. *World J Hepatol* 2025; 17(1): 101798 [DOI: 10.4254/wjh.v17.i1.101798]

Li C, Nan J, Xu BT. *Helicobacter pylori* infection as a contributing factor to metabolic dysfunction-associated steatohepatitis: A population-based insight. *World J Hepatol* 2025; 17(1): 103228 [DOI: 10.4254/wjh.v17.i1.103228]

Jin LY, Wang K, Xu BT. High metabolic dysfunction-associated steatotic liver disease prevalence in type 2 diabetes: Urgent need for integrated screening and lifestyle intervention. *World J Hepatol* 2025; 17(1): 103409 [DOI: [10.4254/wjh.v17.i1.103409](https://doi.org/10.4254/wjh.v17.i1.103409)]

ABOUT COVER

Editorial Board Member of *World Journal of Hepatology*, Maria Jesus Citores, PhD, Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda 28222, Madrid, Spain. mariajesus.citores@salud.madrid.org

AIMS AND SCOPE

The primary aim of *World Journal of Hepatology (WJH, World J Hepatol)* is to provide scholars and readers from various fields of hepatology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJH mainly publishes articles reporting research results and findings obtained in the field of hepatology and covering a wide range of topics including chronic cholestatic liver diseases, cirrhosis and its complications, clinical alcoholic liver disease, drug induced liver disease autoimmune, fatty liver disease, genetic and pediatric liver diseases, hepatocellular carcinoma, hepatic stellate cells and fibrosis, liver immunology, liver regeneration, hepatic surgery, liver transplantation, biliary tract pathophysiology, non-invasive markers of liver fibrosis, viral hepatitis.

INDEXING/ABSTRACTING

The *WJH* is now abstracted and indexed in PubMed, PubMed Central, Emerging Sources Citation Index (ESCI), Scopus, Reference Citation Analysis, China Science and Technology Journal Database, and Superstar Journals Database. The 2024 Edition of Journal Citation Reports® cites the 2023 journal impact factor (JIF) for *WJH* as 2.5; JIF Quartile: Q3. The *WJH*'s CiteScore for 2023 is 4.1 and Scopus CiteScore rank 2023: Hepatology is 41/82.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: *Yu-Qing Zhao*; Production Department Director: *Xiang Li*; Cover Editor: *Xiang Li*.

NAME OF JOURNAL

World Journal of Hepatology

ISSN

ISSN 1948-5182 (online)

LAUNCH DATE

October 31, 2009

FREQUENCY

Monthly

EDITORS-IN-CHIEF

Koo Jeong Kang

EXECUTIVE ASSOCIATE EDITORS-IN-CHIEF

Shuang-Suo Dang

EDITORIAL BOARD MEMBERS

<https://www.wjgnet.com/1948-5182/editorialboard.htm>

PUBLICATION DATE

January 27, 2025

COPYRIGHT

© 2025 Baishideng Publishing Group Inc

PUBLISHING PARTNER

Department of Infectious Diseases, the Second Affiliated Hospital of Xi'an Jiaotong University

INSTRUCTIONS TO AUTHORS

<https://www.wjgnet.com/bpg/gerinfo/204>

GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjgnet.com/bpg/GerInfo/287>

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjgnet.com/bpg/gerinfo/240>

PUBLICATION ETHICS

<https://www.wjgnet.com/bpg/GerInfo/288>

PUBLICATION MISCONDUCT

<https://www.wjgnet.com/bpg/gerinfo/208>

POLICY OF CO-AUTHORS

<https://www.wjgnet.com/bpg/GerInfo/310>

ARTICLE PROCESSING CHARGE

<https://www.wjgnet.com/bpg/gerinfo/242>

STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjgnet.com/bpg/GerInfo/239>

ONLINE SUBMISSION

<https://www.f6publishing.com>

PUBLISHING PARTNER'S OFFICIAL WEBSITE

http://2yuan.xjtu.edu.cn/Html/Departments/Main/Index_21148.html



Small bites, big impact: The importance of evening snacks in patients with advanced chronic liver disease

Federica Perazza, Federico Ravaoli

Specialty type: Gastroenterology and hepatology

Provenance and peer review: Invited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's classification

Scientific Quality: Grade B, Grade B

Novelty: Grade B, Grade B

Creativity or Innovation: Grade A, Grade B

Scientific Significance: Grade A, Grade B

P-Reviewer: Kim SJ; Shi YL

Received: September 9, 2024

Revised: November 8, 2024

Accepted: December 2, 2024

Published online: January 27, 2025

Processing time: 121 Days and 11.7 Hours



Federica Perazza, Federico Ravaoli, Department of Medical and Surgical Sciences, University of Bologna, Bologna 40138, Italy

Corresponding author: Federico Ravaoli, MD, PhD, Research Assistant, Department of Medical and Surgical Sciences, University of Bologna, Via Massarenti 9, Bologna 40138, Italy. f.ravaoli@unibo.it

Abstract

People with advanced chronic liver disease (ACLD) have an enhanced risk of malnutrition, which has multifactorial etiology and is mainly linked to a reduced energy and protein intake; malnutrition is critical for patients with cirrhosis since it is often associated with sarcopenia, a skeletal muscle depletion with a loss of muscle mass and function. Late-evening snacks have been extensively studied, and guidelines are recommended to counteract the effects of prolonged fasting at night in patients with ACLD. However, it has not been fully explored whether late evening snacking is clarified as a milestone to address the nutritional needs of people with ACLD or whether it has a potential role in improving body composition. In this randomised control trial, Yu *et al* demonstrated that long-term nocturnal snacks have the potential to significantly improve body composition by body fat mass, visceral fat area and body cell mass in patients with ACLD. While the improvement in skeletal muscle mass was minor, the promising results in other compositions provide hope for future research and patient care.

Key Words: Nutrition; Cirrhosis; Advanced chronic liver disease; Malnutrition; Sarcopenia; Skeletal muscle mass

©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: This editorial discusses a randomized control trial by Yu *et al* published in the *World Journal of Hepatology*, examining the effect of nocturnal snacks on patients with advanced chronic liver disease. The study aimed to assess late evening snacks' impact on body composition in cirrhosis patients. Findings suggest that nocturnal snacks may improve body fat mass, visceral fat area, and body cell mass, though their effect on skeletal muscle mass is limited. This result underscores the need for additional research on optimizing nutritional interventions in these patients.

Citation: Perazza F, Ravaioli F. Small bites, big impact: The importance of evening snacks in patients with advanced chronic liver disease. *World J Hepatol* 2025; 17(1): 101195

URL: <https://www.wjgnet.com/1948-5182/full/v17/i1/101195.htm>

DOI: <https://dx.doi.org/10.4254/wjh.v17.i1.101195>

INTRODUCTION

Cirrhosis, also named advanced chronic liver disease (ACLD), is the final stage of progressive liver disease, marked by extensive fibrosis where regenerative hepatic nodules substitute the normal liver structure due to chronic liver injury, ultimately leading to liver failure. ACLD is often linked to significant morbidity and mortality[1]. In the early phases, this condition is asymptomatic, configured as compensated ACLD (cACLD), but subsequently, it evolves into decompensated ACLD (dACLD), defined as the first episode of ascites, esophageal variceal bleeding and hepatic encephalopathy[2].

Malnutrition results in changes to body composition and cellular functions caused by insufficient protein and energy intake. This definition is supported by both the Global Leadership Initiative on Malnutrition and the European Society for Clinical Nutrition and Metabolism[3]. Diagnosing, evaluating, and grading malnutrition requires a blend of phenotypic criteria-such as weight loss, decreased body mass index, or reduced muscle mass-and etiological factors, including diminished food intake, poor assimilation, and the existence of acute or chronic disease-related inflammation. Malnutrition is a major concern among ACLD patients, with prevalence rates ranging from 5% to 92%[4]. This prevalence rises with greater disease severity (dACLD) but is also observable in the compensated stage[5,6].

Frequently, in patients with ACLD, malnutrition is associated with sarcopenia, a skeletal muscle depletion with a loss of muscle mass and strength function[7]; in patients with cirrhosis, sarcopenia prevalence varies between 40% and 70%, significantly depending on the specific population studied, methods of assessment and the definition of sarcopenia used [8]. The etiology of sarcopenia is complex and multifactorial and involves gastrointestinal symptoms-prevalent in patients with cirrhosis-(nausea and early satiety) and also connected to high levels of leptin, hypermetabolism due to systemic inflammation, and low levels of physical activity; alcohol consumption, besides worsening liver disease, contributes to developing sarcopenia[9].

Malnutrition, particularly when linked to sarcopenia, complicates ACLD and acts as a standalone risk factor for both disease advancement and outcomes, including increased hospitalization rates and mortality. It also contributes to other ACLD-related complications like hepatic encephalopathy and infections[10,11].

THE IMPORTANCE OF NOCTURNAL LATE-EVENING SNACKS

Patients affected by ACLD experience an imbalance between muscle protein synthesis, typically during the fed state, and protein breakdown, which is present during the fasting state[12-14]. Cirrhosis is characterised by hypermetabolism that leads to accelerated starvation even after a brief fasting period, with an early shift from glucose to lipid metabolism due to reduced glycogen storage[15,16]. Indeed, during fasting, in patients with ACLD, glucose oxidation and glycogenolysis diminish in favour of fat oxidation and gluconeogenesis[16], which determine increased protein consumption and, finally, skeletal muscle depletion and sarcopenia[17].

Since the most prolonged period of starvation occurs during the night, between dinner and breakfast, late-evening snack consumption counteracts the progression to a catabolic state and improves sarcopenia[18]. Moreover, late-evening snacks help stabilise glucose levels in the blood[18]. Finally, nocturnal snacks prevent muscle depletion and promote metabolic homeostasis[18].

NOCTURNAL SNACKS AND BODY COMPOSITION

Body composition is a crucial tool in indirectly assessing the nutritional state since it allows the evaluation of fat and muscle mass, thus indirectly evaluating the presence of sarcopenia[19].

Several studies have explored the impact of nocturnal snacks on liver disease. Recently, we summarised the evidence about the impact of late-evening snacks in patients with ACLD[14].

Most papers studied the positive effect of nocturnal snacks on strong outcomes, such as liver enzymes, hepatic encephalopathy and death[20,21]. Nevertheless, a prospective study by Kobayashi *et al*[22] evaluated the modifications in body composition through bioelectrical impedance analysis (BIA) after introducing late evening snacks in patients undergoing liver surgery for hepatocellular carcinoma or for metastasis from colorectal cancer. The authors[22] found that body cell mass (BCM) and skeletal muscle volume were higher in the nocturnal snack group compared with the control group.

However, the effect of late-evening snacks on body composition still needs to be explored further.

In this relevant paper "Effects of nocturnal snacks on body composition in patients with liver cirrhosis" to be published in *World Journal of Hepatology*, Yu *et al*[23] studied the effect of late-evening snacks on body composition in a cohort of 70 patients with ACLD compared to 30 healthy controls. The differences in body composition were evaluated using multi-frequency BIA (InBody 720, a body composition analyser). Bioelectrical impedance permits the detection of body composition utilising the different impedances encountered by the current passing through the cells and intercellular

mass, to calculate the intracellular and extracellular fluid content of the subject and to derive the protein, fat, skeletal muscle substance, body cell count, and mineral contentment. Although computed tomography is the gold standard for body composition assessment, bioelectrical impedance avoids radiation exposure and allows regular monitoring of changes. The authors confirmed that at baseline, body fat mass (BFM), skeletal muscle mass (SMM), free fat mass, visceral fat area (VFA) and BCM were significantly lower in ACLD patients than in the healthy control group. Subsequently, the patients were randomised into a standard diet group (three meals a day) and a late evening snacks group (three meals a day + nocturnal snacks) for three months of intervention. The authors showed, at the end of follow-up, that in patients with ACLD, late-evening snacks ameliorate the body composition indicators with an improvement in BFM, VFA and BCM; on the other side, however, SMM was not improved in both groups. In light of these results, several considerations could be made. First, since there are different proportions between patients with cACLD *vs* dACLD with distinct etiologies of liver disease, it could be intriguing to evaluate if differences in body composition are detectable after intervention, considering the basal condition. Second, as the duration of intervention was limited, it could be considered that a longer supplementation may positively impact body composition, including SMM. In fact, in a randomized controlled trial, Ruiz-Margáin *et al*[24] highlighted that a six-month supplementation with branched-chain amino acids-in addition to a high-fibre, high-protein diet-increases muscle mass without raising the levels of ammonia or development of hepatic encephalopathy.

Third, since the authors showed that VFA increased after three months in the nocturnal snack group, this result could be insidious, especially for patients with an elevated body mass index at the baseline. Indeed, the increase in VFA exposes the patient to the risk of developing or worsening insulin resistance, a critical mechanism which may exacerbate liver damage. In fact, further investigations are required to clarify if a specific composition of late evening snack may impact positively on SMM without worsening VFA.

CONCLUSION

Nocturnal snacks are fundamental to addressing the specific nutritional needs of patients with ACLD. Still, it remains to be seen if they may have a potential role in ameliorating SMM content detected through body composition analysis. Moreover, further studies are necessary to investigate if the different formulations (quantity of proteins, carbs and lipids) of the nocturnal snack may specifically affect body composition, particularly in preserving skeletal muscle mass and preventing sarcopenia.

FOOTNOTES

Author contributions: Perazza F and Ravaioli F wrote the paper; Ravaioli F designed the overall concept and outline of the manuscript, edited the manuscript; all of the authors read and approved the final version of the manuscript to be published.

Conflict-of-interest statement: All authors declare no conflict of interest in publishing the manuscript.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

Country of origin: Italy

ORCID number: Federica Perazza 0009-0004-0554-7504; Federico Ravaioli 0000-0002-1142-8585.

S-Editor: Luo ML

L-Editor: A

P-Editor: Zhao YQ

REFERENCES

- 1 **Ginès P**, Krag A, Abraldes JG, Solà E, Fabrellas N, Kamath PS. Liver cirrhosis. *Lancet* 2021; **398**: 1359-1376 [PMID: 34543610 DOI: 10.1016/S0140-6736(21)01374-X]
- 2 **D'Amico G**, Morabito A, D'Amico M, Pasta L, Malizia G, Rebora P, Valsecchi MG. Clinical states of cirrhosis and competing risks. *J Hepatol* 2018; **68**: 563-576 [PMID: 29111320 DOI: 10.1016/j.jhep.2017.10.020]
- 3 **Cederholm T**, Bosaeus I, Barazzoni R, Bauer J, Van Gossum A, Klek S, Muscaritoli M, Nyulasi I, Ockenga J, Schneider SM, de van der Schueren MA, Singer P. Diagnostic criteria for malnutrition - An ESPEN Consensus Statement. *Clin Nutr* 2015; **34**: 335-340 [PMID: 25799486 DOI: 10.1016/j.clnu.2015.03.001]
- 4 **Traub J**, Reiss L, Aliwa B, Stadlbauer V. Malnutrition in Patients with Liver Cirrhosis. *Nutrients* 2021; **13**: 540 [PMID: 33562292 DOI: 10.3390/nu13020540]
- 5 **Chaudhry A**, Toori KU, Shaikh JI. To determine correlation between biochemical parameters of nutritional status with disease severity in

- HCV related liver cirrhosis. *Pak J Med Sci* 2018; **34**: 154-158 [PMID: 29643898 DOI: 10.12669/pjms.341.14011]
- 6 **Naqvi IH**, Mahmood K, Salekeen S, Akhter ST. Determining the frequency and severity of malnutrition and correlating it with the severity of liver cirrhosis. *Turk J Gastroenterol* 2013; **24**: 415-422 [PMID: 24557965 DOI: 10.4318/tjg.2013.0637]
 - 7 **Aby ES**, Saab S. Frailty, Sarcopenia, and Malnutrition in Cirrhotic Patients. *Clin Liver Dis* 2019; **23**: 589-605 [PMID: 31563213 DOI: 10.1016/j.cld.2019.06.001]
 - 8 **Tandon P**, Montano-Loza AJ, Lai JC, Dasarathy S, Merli M. Sarcopenia and frailty in decompensated cirrhosis. *J Hepatol* 2021; **75** Suppl 1: S147-S162 [PMID: 34039486 DOI: 10.1016/j.jhep.2021.01.025]
 - 9 **Vasques J**, Guerreiro CS, Sousa J, Pinto M, Cortez-Pinto H. Nutritional support in cirrhotic patients with sarcopenia. *Clin Nutr ESPEN* 2019; **33**: 12-17 [PMID: 31451247 DOI: 10.1016/j.clnesp.2019.07.011]
 - 10 **Lindqvist C**, Majeed A, Wahlin S. Body composition assessed by dual-energy X-ray absorptiometry predicts early infectious complications after liver transplantation. *J Hum Nutr Diet* 2017; **30**: 284-291 [PMID: 27709718 DOI: 10.1111/jhn.12417]
 - 11 **Ruiz-Margáin A**, Macías-Rodríguez RU, Duarte-Rojo A, Ríos-Torres SL, Espinosa-Cuevas Á, Torre A. Malnutrition assessed through phase angle and its relation to prognosis in patients with compensated liver cirrhosis: a prospective cohort study. *Dig Liver Dis* 2015; **47**: 309-314 [PMID: 25618555 DOI: 10.1016/j.dld.2014.12.015]
 - 12 **European Association for the Study of the Liver**. EASL Clinical Practice Guidelines on nutrition in chronic liver disease. *J Hepatol* 2019; **70**: 172-193 [PMID: 30144956 DOI: 10.1016/j.jhep.2018.06.024]
 - 13 **Lai JC**, Tandon P, Bernal W, Tapper EB, Ekong U, Dasarathy S, Carey EJ. Malnutrition, Frailty, and Sarcopenia in Patients With Cirrhosis: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. *Hepatology* 2021; **74**: 1611-1644 [PMID: 34233031 DOI: 10.1002/hep.32049]
 - 14 **Leoni L**, Valoriani F, Barbieri R, Pambianco M, Vinciguerra M, Sicuro C, Colecchia A, Menozzi R, Ravaoli F. Unlocking the Power of Late-Evening Snacks: Practical Ready-to-Prescribe Chart Menu for Patients with Cirrhosis. *Nutrients* 2023; **15**: 3471 [PMID: 37571408 DOI: 10.3390/nu15153471]
 - 15 **McCullough AJ**, Mullen KD, Kalhan SC. Body cell mass and leucine metabolism in cirrhosis. *Gastroenterology* 1992; **102**: 1325-1333 [PMID: 1551538]
 - 16 **McCullough AJ**, Mullen KD, Kalhan SC. Defective nonoxidative leucine degradation and endogenous leucine flux in cirrhosis during an amino acid infusion. *Hepatology* 1998; **28**: 1357-1364 [PMID: 9794922 DOI: 10.1002/hep.510280526]
 - 17 **Brosnan JT**. Comments on metabolic needs for glucose and the role of gluconeogenesis. *Eur J Clin Nutr* 1999; **53** Suppl 1: S107-S111 [PMID: 10365987 DOI: 10.1038/sj.ejcn.1600748]
 - 18 **Tsien CD**, McCullough AJ, Dasarathy S. Late evening snack: exploiting a period of anabolic opportunity in cirrhosis. *J Gastroenterol Hepatol* 2012; **27**: 430-441 [PMID: 22004479 DOI: 10.1111/j.1440-1746.2011.06951.x]
 - 19 **Holmes CJ**, Racette SB. The Utility of Body Composition Assessment in Nutrition and Clinical Practice: An Overview of Current Methodology. *Nutrients* 2021; **13**: 2493 [PMID: 34444653 DOI: 10.3390/nu13082493]
 - 20 **Hanai T**, Shiraki M, Imai K, Suetsugu A, Takai K, Shimizu M. Late Evening Snack with Branched-Chain Amino Acids Supplementation Improves Survival in Patients with Cirrhosis. *J Clin Med* 2020; **9**: 1013 [PMID: 32260139 DOI: 10.3390/jcm9041013]
 - 21 **Guo YJ**, Tian ZB, Jiang N, Ding XL, Mao T, Jing X. Effects of Late Evening Snack on Cirrhotic Patients: A Systematic Review and Meta-Analysis. *Gastroenterol Res Pract* 2018; **2018**: 9189062 [PMID: 29805447 DOI: 10.1155/2018/9189062]
 - 22 **Kobayashi K**, Kaneko J, Yamaguchi T, Kawaguchi Y, Arita J, Akamatsu N, Ishizawa T, Sekine R, Ijichi H, Kubota N, Fukatsu K, Kokudo N, Hasegawa K. Late-Evening Carbohydrate and Branched-Chain Amino Acid Snacks Improve the Nutritional Status of Patients Undergoing Hepatectomy Based on Bioelectrical Impedance Analysis of Body Composition. *Gastrointest Tumors* 2019; **6**: 81-91 [PMID: 31768352 DOI: 10.1159/000501452]
 - 23 **Yu YB**, Fu XJ, Xu GF, Niu LY, Duan RN, Yao J, Zhao NH. Effects of nocturnal snacks on body composition in patients with liver cirrhosis. *World J Hepatol* 2024; **16**: 1458-1467 [DOI: 10.4254/wjh.v16.i12.1458]
 - 24 **Ruiz-Margáin A**, Macías-Rodríguez RU, Ríos-Torres SL, Román-Calleja BM, Méndez-Guerrero O, Rodríguez-Córdova P, Torre A. Effect of a high-protein, high-fiber diet plus supplementation with branched-chain amino acids on the nutritional status of patients with cirrhosis. *Rev Gastroenterol Mex (Engl Ed)* 2018; **83**: 9-15 [PMID: 28408059 DOI: 10.1016/j.rgmx.2017.02.005]



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-3991568
E-mail: office@baishideng.com
Help Desk: <https://www.f6publishing.com/helpdesk>
<https://www.wjgnet.com>

